Rapport TherapeuticsRAPP -0.60%14 Current Ratio is 27.08 as of Mar. 2026, which is at its 10-year median of 27.08. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Rapport Therapeutics ranks better than 95.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Rapport Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 27.08.
Rapport Therapeutics has a current ratio of 27.08. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Rapport Therapeutics's Current Ratio or its related term are showing as below:
RAPP'
s Current Ratio Range Over the Past 10 Years
Min: 17.14 Med: 27.08 Max: 45.91
Current: 27.08
During the past 4 years, Rapport Therapeutics's highest Current Ratio was 45.91. The lowest was 17.14. And the median was 27.08.
RAPP's Current Ratio is ranked better than 95.53% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs RAPP: 27.08
Rapport Therapeutics (NAS:RAPP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Rapport Therapeutics Current Ratio Related Terms
Rapport Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPP vs SION, TYRA, IOVA: Current Ratio Comparison
For the Biotechnology subindustry, Rapport Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Current Ratio of 27.08 as of Mar. 2026. This is near median its historical median of 27.08. Over the past decade, Rapport Therapeutics' Current Ratio has ranged from 17.14 to 45.91. According to the industry distribution chart, Rapport Therapeutics ranks #63 out of 1410 companies in the Biotechnology industry, placing it in the top 4.5%.
Is Rapport Therapeutics' Current Ratio too high?
Rapport Therapeutics' current Current Ratio of 27.08 is near median its 10-year median of 27.08. Over the past 10 years, this metric has ranged from a low of 17.14 to a high of 45.91. The Biotechnology industry median Current Ratio is 3.89. Rapport Therapeutics' value of 27.08 is 596.1% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #63 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Current Ratio compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #63 out of 1410 companies for Current Ratio. This places Rapport Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Rapport Therapeutics' value of 27.08 is 596.1% above this benchmark. Historically, Rapport Therapeutics' own Current Ratio has ranged from 17.14 to 45.91 over the past decade. While the company's 10-year median is 27.08 vs. the industry median of 3.89, Rapport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Current Ratio of 27.08 is 596.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Current Ratio is 27.08, which is near median its own 10-year median of 27.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Current Ratio of 27.08. The current Current Ratio is 27.08, which is near median its 10-year median of 27.08 and 596.1% above the Biotechnology industry median of 3.89. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Current Ratio is 27.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
